Systemic arterial hypertension (SAH) is a risk factor for 9.4 million deaths worldwide. In Brazil, HAS assigned an annual cost of about 1.5 billion to the Public Health System (PHS). The Pharmaceutical Care (PC) is able to avoid complications of hypertension and reduce health costs. The PC economic analysis in long-term showed that the net return on investment in this pharmaceutical practice can reach R$ 3,791,111.13 in ten years. One pharmacoeconomic tool for the implementation of the PC in the PHS was created in accordance with the methodology developed for this analysis. However, for this tool become applicable in society is necessary its development and validation. In addition, it is possible to improve it by adding the measurement of monetary return when evaluating morbidities associated complications of hypertension. This study aims to develop and validate the pharmacoeconomic tool to aid in the implementation of the PC in the PHS incorporating Human Disease Netwok to predict the epidemiological impact and return on investment of this pharmaceutical practice. This is a pharmacoeconomic study with application of modeling, nested in a systematic review. The data of the systematic review will be tabulated and applied in the restructuring and development of pharmacoeconomic tool. Additionally, it will be structured a Markov model to project the incidence of diseases associated with complications of hypertension by proteomic studies that resorts the Human Netwok Disease. Thus, this tool will be enhanced for its validation and applicability. It is hoped that the validation of this tool to encourage the implementation of the PC in the PHS and thus improve blood pressure control rate among hypertensive patients, quality of life, reduce morbidities and deaths associated with SAH, reduce spending with indirect costs to health, as well as assisting in the planning and optimization of health resources. There is also the pretension to foster a possible subarea in pharmacoeconomics with the use of proteomics.
News published in Agência FAPESP Newsletter about the scholarship: